327 related articles for article (PubMed ID: 24438510)
1. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
3. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation.
Leung TF; Chik KW; Li CK; Lai H; Shing MM; Chan PK; Lee V; Yuen PM
Bone Marrow Transplant; 2000 Jan; 25(2):167-72. PubMed ID: 10673675
[TBL] [Abstract][Full Text] [Related]
4. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
5. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
[TBL] [Abstract][Full Text] [Related]
6. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
7. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
[TBL] [Abstract][Full Text] [Related]
8. Visceral varicella zoster virus infection after allogeneic stem cell transplantation.
Doki N; Miyawaki S; Tanaka M; Kudo D; Wake A; Oshima K; Fujita H; Uehara T; Hyo R; Mori T; Takahashi S; Okamoto S; Sakamaki H;
Transpl Infect Dis; 2013 Jun; 15(3):314-8. PubMed ID: 23551634
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group.
Onozawa M; Hashino S; Haseyama Y; Hirayama Y; Iizuka S; Ishida T; Kaneda M; Kobayashi H; Kobayashi R; Koda K; Kurosawa M; Masauji N; Matsunaga T; Mori A; Mukai M; Nishio M; Noto S; Ota S; Sakai H; Suzuki N; Takahashi T; Tanaka J; Torimoto Y; Yoshida M; Fukuhara T
Biol Blood Marrow Transplant; 2009 Jun; 15(6):724-9. PubMed ID: 19450757
[TBL] [Abstract][Full Text] [Related]
10. Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.
Onozawa M; Hashino S; Takahata M; Fujisawa F; Kawamura T; Nakagawa M; Kahata K; Kondo T; Ota S; Tanaka J; Imamura M; Asaka M
J Clin Microbiol; 2006 Dec; 44(12):4441-3. PubMed ID: 17035500
[TBL] [Abstract][Full Text] [Related]
11. Persistence and antiviral resistance of varicella zoster virus in hematological patients.
van der Beek MT; Vermont CL; Bredius RG; Marijt EW; van der Blij-de Brouwer CS; Kroes AC; Claas EC; Vossen AC
Clin Infect Dis; 2013 Feb; 56(3):335-43. PubMed ID: 23074321
[TBL] [Abstract][Full Text] [Related]
12. Prevention of VZV infection in immunosuppressed patients using antiviral agents.
Boeckh M
Herpes; 2006 Nov; 13(3):60-5. PubMed ID: 17147908
[TBL] [Abstract][Full Text] [Related]
13. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
Vermont CL; Jol-van der Zijde EC; Hissink Muller P; Ball LM; Bredius RG; Vossen AC; Lankester AC
Transpl Infect Dis; 2014 Apr; 16(2):188-94. PubMed ID: 24438482
[TBL] [Abstract][Full Text] [Related]
14. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
[TBL] [Abstract][Full Text] [Related]
15. Acyclovir treatment prevents varicella-zoster virus replication in PBMC during viremia.
Wolff MH; Schünemann S
New Microbiol; 1999 Oct; 22(4):309-14. PubMed ID: 10555200
[TBL] [Abstract][Full Text] [Related]
16. Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation.
Suzuki J; Ashizawa M; Okuda S; Wada H; Sakamoto K; Terasako K; Sato M; Kimura SI; Kikuchi M; Nakasone H; Kako S; Yamazaki R; Oshima K; Nishida J; Kanda Y
Transpl Infect Dis; 2012 Aug; 14(4):E7-12. PubMed ID: 22340704
[TBL] [Abstract][Full Text] [Related]
17. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
18. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
[TBL] [Abstract][Full Text] [Related]
19. Visceral varicella zoster virus (VZV) after allogeneic hematopoietic stem cell transplant (HSCT) in pediatric patients with chronic graft-versus-host disease (cGVHD).
Peritz DC; Duncan C; Kurek K; Perez-Atayde AR; Lehmann LE
J Pediatr Hematol Oncol; 2008 Dec; 30(12):931-4. PubMed ID: 19131784
[TBL] [Abstract][Full Text] [Related]
20. Late-onset visceral varicella-zoster virus infection presented as acute liver failure after allogeneic hematopoietic stem cell transplantation.
Kikuchi T; Arai M; Koda Y; Kato J; Shimizu T; Katano H; Fujii-Nishimura Y; Sakamoto M; Ebinuma H; Nakamoto N; Kanai T; Okamoto S; Mori T
Transpl Infect Dis; 2019 Aug; 21(4):e13121. PubMed ID: 31127967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
